Jeffrey Cooper
Directeur/Membre du Conseil chez Nexcella, Inc.
Profil
Jeffrey H.
Cooper is currently a Director at Nexcella, Inc. He previously worked as a Director-Business Analysis at Syntex Corp.
from 1983 to 1995, Vice President-Finance at Matrix Pharmaceutical, Inc. from 1998 to 2002, Chief Financial Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. from 2007 to 2012, and Chief Financial Officer at Humanigen, Inc. in 2012-2013.
He also served as an Independent Director at Sierra Oncology, Inc. from 2016 to 2022 and Tobira Therapeutics, Inc. from 2015 to 2016.
Additionally, he worked as a Controller at Foundation Health Systems, Inc. and holds an undergraduate degree from the University of California, Los Angeles and an MBA from Santa Clara University.
Postes actifs de Jeffrey Cooper
| Sociétés | Poste | Début |
|---|---|---|
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Directeur/Membre du Conseil | 20/06/2023 |
Anciens postes connus de Jeffrey Cooper
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/07/2022 |
| TOBIRA THERAPEUTICS INC | Directeur/Membre du Conseil | 31/10/2016 |
| HUMANIGEN, INC. | Directeur Financier/CFO | 14/10/2013 |
| BIOMARIN PHARMACEUTICAL INC. | Directeur Financier/CFO | 01/05/2012 |
Matrix Pharmaceutical, Inc.
 Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | Directeur Financier/CFO | 01/01/2002 |
Formation de Jeffrey Cooper
| University of California, Los Angeles | Undergraduate Degree |
| Santa Clara University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | Health Technology |
| Syntex Corp. | Health Technology |
| Foundation Health Systems, Inc. | Health Services |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
